JP2021501213A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501213A5
JP2021501213A5 JP2020543683A JP2020543683A JP2021501213A5 JP 2021501213 A5 JP2021501213 A5 JP 2021501213A5 JP 2020543683 A JP2020543683 A JP 2020543683A JP 2020543683 A JP2020543683 A JP 2020543683A JP 2021501213 A5 JP2021501213 A5 JP 2021501213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
dose
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501213A (ja
JP7286665B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/112714 external-priority patent/WO2019085902A1/en
Publication of JP2021501213A publication Critical patent/JP2021501213A/ja
Publication of JP2021501213A5 publication Critical patent/JP2021501213A5/ja
Application granted granted Critical
Publication of JP7286665B2 publication Critical patent/JP7286665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543683A 2017-10-31 2018-10-30 ＩｇＥ介在アレルギー性疾患の治療 Active JP7286665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579416P 2017-10-31 2017-10-31
US62/579,416 2017-10-31
PCT/CN2018/112714 WO2019085902A1 (en) 2017-10-31 2018-10-30 Treating ige-mediated allergic diseases

Publications (3)

Publication Number Publication Date
JP2021501213A JP2021501213A (ja) 2021-01-14
JP2021501213A5 true JP2021501213A5 (https=) 2021-09-30
JP7286665B2 JP7286665B2 (ja) 2023-06-05

Family

ID=66332803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543683A Active JP7286665B2 (ja) 2017-10-31 2018-10-30 ＩｇＥ介在アレルギー性疾患の治療

Country Status (13)

Country Link
US (2) US11439682B2 (https=)
EP (1) EP3703753A4 (https=)
JP (1) JP7286665B2 (https=)
KR (1) KR102859911B1 (https=)
CN (1) CN111741768B (https=)
AU (1) AU2018360999A1 (https=)
BR (1) BR112020008488A2 (https=)
CA (1) CA3079992A1 (https=)
IL (1) IL277911B2 (https=)
MX (1) MX421215B (https=)
TW (1) TWI821209B (https=)
WO (1) WO2019085902A1 (https=)
ZA (1) ZA202002247B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240191000A1 (en) * 2021-04-02 2024-06-13 Oneness Biotech Co., Ltd. High concentration antibody formulations
CN118119641A (zh) * 2021-10-12 2024-05-31 联合生物制药股份有限公司 Ige调节的疾病的治疗
CN114028731B (zh) * 2021-12-10 2024-01-26 固安翌光科技有限公司 腰部塑形光疗装置

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006138A1 (en) 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
DK0493446T3 (da) 1989-09-15 1997-08-11 Tanox Biosystems Inc Behandling af autoimmunsygdom.
SG70982A1 (en) 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
US5281699A (en) 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
AU9016591A (en) 1990-10-25 1992-05-26 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
AU3515597A (en) 1997-05-30 1998-12-30 Tanox Biosystems, Inc. Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide
EP2361635A3 (en) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
AUPS158502A0 (en) 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2007131129A2 (en) 2006-05-03 2007-11-15 Guthrie Foundation For Education & Research Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
PT2132230E (pt) 2007-03-22 2014-07-17 Genentech Inc Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana
US8460664B2 (en) * 2009-02-25 2013-06-11 Academia Sinica Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes
WO2011066374A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011108008A2 (en) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
EP2838919A4 (en) * 2012-04-20 2016-03-23 Academia Sinica ANTIBLE ANTIBODIES BINDING TO THE TRANSITION BETWEEN CH4 AND C EPSILON MX DOMAINS
PL2892927T3 (pl) * 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体

Similar Documents

Publication Publication Date Title
US12454571B2 (en) Biopharmaceutical compositions
JP7046088B2 (ja) 抗ｒｓｖモノクローナル抗体製剤
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
CN111372948A (zh) 用il-17拮抗剂治疗化脓性汗腺炎
US11976113B2 (en) Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2018515493A5 (https=)
JP2020507587A (ja) 化膿性汗腺炎の処置
JP2021501213A5 (https=)
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
WO2019020069A1 (zh) 一种sost抗体药物组合物及其用途
US20240067716A1 (en) Ionic liquid formulations for treating inflammatory and autoimmune diseases
IL277911B1 (en) Treatment of IgE-mediated allergic diseases
WO2022017468A1 (zh) Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
JP7804590B2 (ja) 抗ｉｌ－３３抗体の処方物
WO2023001228A1 (zh) 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途
WO2020063668A1 (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
US20240043524A1 (en) Interleukin 5 binding protein dosage regimen
WO2021233408A1 (zh) 抗α-溶血素的抗体及其稳定制剂
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
CN117771379B (zh) 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
IL303350A (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
EA045933B1 (ru) Водная фармацевтическая композиция левилимаба и ее применение